SII seeks permission for regular marketing for Covishield

New Delhi, 25 October

Pointing out that over 100 crore doses of Kovidshield had been supplied to India and several other countries, Serum Institute of India on Monday sought routine marketing approval for the Covid vaccine, which is currently available in the country, official sources said. Authorized for emergency use.

The application, sent by Prakash Kumar Singh, director, government and regulatory affairs, SII, to the Drugs Controller General of India (DCGI), comes just days after PM Narendra Modi held a meeting with domestic Covid-19 vaccine manufacturers.

If DCGI is granted regular marketing authorisation, Kovichid will be the second vaccine in the world to receive such approval. Pfizer-BioNtech’s Covid-19 vaccine has received full US FDA approval for use in individuals 16 years of age and older. — PTI